Sandip Vasavada, MD
Urology · Cleveland, OHNPI 1356306328
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $159,610 of the $262,832 with a category attached, or 60.7%. Medtronic accounts for 75.5% of it on its own, with 19 other manufacturers making up the rest. Among urology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 542 payments — averaging $484.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$199K
- Bluewind Medical$24K
- Astellas Pharma Inc$21K
- Purdue Pharma L.p.$7K
- AbbVie$3K
- Provepharm Inc.$3K
- plus $6K from 14 others
Across 13 payments — averaging $19,174 each. An ownership or investment interest held by the physician or an immediate family member.
- SPR Therapeutics, Inc$211K
- Checkpoint Surgical, Inc$38K
What the payments were for
- Consulting fees$24,5919%
- Speaking & faculty fees$159,61061%
- Grants$1210%
- Travel & lodging$59,66723%
- Food & beverage$18,7557%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 386 | $198,538 |
| Bluewind Medical | 14 | $24,172 |
| Astellas Pharma Inc | 4 | $21,158 |
| Purdue Pharma L.p. | 1 | $6,600 |
| AbbVie(2 entities) | 53 | $3,315 |
| Provepharm Inc. | 4 | $3,207 |
| Axonics, Inc. | 24 | $2,274 |
| Boston Scientific | 13 | $877 |
| Coloplast | 7 | $764 |
| Urovant Sciences Inc | 4 | $372 |
| C. R. Bard, Inc. & Subsidiaries | 7 | $360 |
| Rochester Medical Corporation | 13 | $357 |
| Sumitomo Pharma America, Inc. | 3 | $268 |
| Caldera Medical, Inc | 3 | $152 |
| Antares Pharma, Inc. | 1 | $138 |
| Laborie Medical Technologies Corp. | 1 | $120 |
| Astellas Pharma US Inc | 1 | $83 |
| Contura, Inc. | 1 | $42 |
| BD | 1 | $21 |
| 180 Medical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$175,842
- MYRBETRIQ$21,085
- REVI$16,178
- ALTAVIVA$5,800
- RENOVA$5,250
- BLUDIGO$3,200
- BOTOX$2,026
- Axonics r-SNM System$1,112
- ALTIS$554
- Bulkamid$270
- Lynx System$252
- GEMTESA$244
- INTELLIS ADAPTIVESTIM$212
- Axonics$149
- NOCDURNA$138
- APS$135
- Bard Urinary Drainage Bag$124
- Desara$119
- SOLYX BLUE$117
- Porges Coloplast$115
How this compares
$262,832 in reported general payments places this provider in the 95th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 154 | $83,413 |
| GemtesaVibegron | 86 | $52,474 |
| Trospium Chloride ErTrospium Chloride | 81 | $7,978 |
| Estradiol | 94 | $5,508 |
| Methenamine Hippurate | 39 | $3,854 |
| Trospium Chloride | 94 | $3,705 |
| Cephalexin | 51 | $374 |
| Oxybutynin Chloride ErOxybutynin Chloride | 31 | $369 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $230 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $80 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $83 | $83,413154 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $268 | $52,47486 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 485 urology providers in Ohio.
Other urology in Cleveland
- Howard GoldmanCleveland$721K
- Sriharan SivalingamCleveland$276K
- Jihad KaoukCleveland$234K
- Ruben OlivaresCleveland$184K
- Raymond RackleyCleveland$152K
- Petar BajicCleveland$149K
- Jorge Gutierrez AcevesCleveland$90K
- Kenneth AngermeierCleveland$69K
- Roger KhouriCleveland$57K
- Xinyuan ZhangCleveland$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.